Table 2.
Epilepsy characteristics of the surveyed cohort.
| Variables | BNT162b2First dose N=15(13.5) | BNT162b2Second dose N=35(31.5) | ChAdOx1 nCoV-19First dose N=32 (28.8) | Not receive yet N=29(26.1) | Total |
|---|---|---|---|---|---|
| Epilepsy duration | |||||
| • two years or less | 1(0.9) | 6(5.4) | 4(3.2) | 6(5.4) | 18(16.2) |
| • more than two years | 14(12.6) | 28(25.2) | 28(25.2) | 23(20.7) | 93(83.8) |
| Number of ASM | |||||
| • one drug • two drugs • three or more |
8(7.2) 5(4.5) 2(1.9) |
15(13.5) 12(10.8) 8(7.2) |
12(10.8) 13(11.7) 7(6.3) |
19(17.1) 8(7.2) 2(1.9) |
54(48.6) 38(34.2) 19(17.1) |
| Type of epilepsy | |||||
| • generalized tonic-clonic • focal with loss awareness • focal without loss awareness • absence • myoclonus |
3(2.7) 1(0.9) 5(4.5) 6(5.4) 0 |
11(9.9) 7(6.3) 7(6.3) 2(1.9) 8(7.2) |
10(9) 11(9.9) 7(6.3) 1(0.9) 3(2.7) |
11(9.9) 9(8.1) 5(4.5) 1(0.9) 3(2.7) |
35(31.5) 28(25.2) 24(21.6) 10(9) 14(12.6) |
| Number of seizure per month within last 3 months (mean/SD) | 0.733(1.44) | 1.17(1.94) | 2.03(4.07) | 1.89(4.84) | |
| History of status epilepticus | |||||
| • Yes • No |
1 (0.9) 14(12.6) |
3(2.7) 32(28.3) |
3(2.7) 29(26.1) |
7(6.3) 22(19.8) |
14(12.6) 97(87.4) |